Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIKTORIA-2 first-line gedatolisib versus ribociclib in HR-positive/HER2-negative advanced breast cancer
2024-518933-28-01Phase 3Authorised
- Sponsor
- Celcuity Inc.
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of gedatolisib in breast cancer (2 arms), sponsored by Celcuity Inc. Primary endpoints: Study 1 progression-free survival and Study 2 progression-free survival. Planned start Oct 2026; status: authorised.
02
Drugs
gedatolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-518933-28-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518933-28-01.